Eutelsat Group (OTCMKTS:EUTLF) and SWEDISH ORPHAN/S (OTCMKTS:SWTUY) Financial Comparison

SWEDISH ORPHAN/S (OTCMKTS:SWTUY) and Eutelsat Group (OTCMKTS:EUTLF) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, dividends, earnings, valuation and risk.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for SWEDISH ORPHAN/S and Eutelsat Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SWEDISH ORPHAN/S	0	0	0	0	0.00
Eutelsat Group	1	0	0	0	1.00

Profitability

This table compares SWEDISH ORPHAN/S and Eutelsat Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%
Eutelsat Group	N/A	N/A	N/A

Volatility & Risk

SWEDISH ORPHAN/S has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500. Comparatively, Eutelsat Group has a beta of -1.02, meaning that its share price is 202% less volatile than the S&P 500.

Earnings & Valuation

This table compares SWEDISH ORPHAN/S and Eutelsat Group”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76
Eutelsat Group	$1.31 billion	0.78	-$335.31 million	N/A	N/A

SWEDISH ORPHAN/S has higher earnings, but lower revenue than Eutelsat Group.

Summary

SWEDISH ORPHAN/S beats Eutelsat Group on 6 of the 8 factors compared between the two stocks.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

About Eutelsat Group

Eutelsat Group, together with its subsidiaries, engages in the operation of telecommunication satellites. It provides capacity for video services, fixed data, and government services; and capacity in connectivity applications, such as fixed broadband and mobile connectivity. The company offers its services under the Eutelsat brand directly and through distributors. It operates 36 satellites in geostationary orbit. The company serves satellite-based video, business and broadband networks, and mobile services mainly to international telecommunications operators and broadcasters, corporate network integrators, companies, telecom operators, and government agencies in France, Italy, the United Kingdom, rest of Europe, the Americas, the Middle East, Africa, Asia, and internationally. The company was formerly known as Eutelsat Communications S.A. and changed its name to Eutelsat Group in October 2023. Eutelsat Group was founded in 1977 and is headquartered in Issy-les-Moulineaux, France.